Document evkO5yV2Z0aOmXrxnr2RNzO0e

Larry IL Zobel,MD, MTH StaffVice President and Medical Director 3M MedicalDepartinent 3M Center,Building220-2E-02 PO Box 33220 St.Paul,MN 55133-3220 651733 5181 Office 651733 5152 Facsiiy@le April25,2000 Dr. Oscar Hernandez US EPA/OPPT/CCD (7405) 401 M StreetS,W Room E615B Washington,DC 20460 VIA FEDERAL EXPRESS 8@l@8 13 Dear Dr. Hernandez: Enclosedarecopiesof thefollowingdocumentswhich were inadvertentloymittedfrom our packagesentto you lastFriday,April21,2000: 1. Protocol418-008 Combined oral(gavage)fertilitdye,velopmentaland perinatal/postnatal reproductiotnoxicitsytudyofPFOS inrats(Sponsor'studynumber: 6295.9),TableE20, 1-3; 2. Harb, R.V., Hartman, H.A. and Cox, R.H. (1994),Preventionof fluvastatiinnduced toxicitym,ortalitya,nd cardiacmyopathy in pregnantratesby mevalonic acid supplementatioTne.ratology5,0,19-26; 3. Haughom, B. and Spydevold,0. (1992),Ile mechanism underlyingthehyperlipen-@ecffect of perfluorooctanoaiccid(PFOA), perfluorooctastuelphonicacid (PFOS) and clofibric acid.BiochimicaetBiophysicaActa,1128,65-72; 4. Levin,M.S. Pitt,A.J.A.,Schwartz,A.L.,Edwards,P.A. and Gordon, J.1.(1989), Developmentalchanges inthe expressionof genesinvolvedin cholesterobliosynthesiasnd lipidtransportinhuman and ratfetaland neonatallivers.Biochimica etBiophysicaActa, 1003, 293-300;and 5. Interofficmemo from Tom Kestnerto Leo Gehlhoff,"FluorochemicalIsomer Distribution by '9F-NMR Spectroscopy,D"ecember 1,1997. Ifyou have any questionsor need additionailnformationp,leasefeelfreeto contactme at 651-733-5181. Sincerely, @@@Z eo4bl, M StaffVice President& MedicalDirector LRZ:Ianj Enclosures